CCCS on Jan 13 accepted a joint application from the parties for a decision on whether the proposed transaction would be anti-competitive.

The Competition and Consumer Commission of Singapore (CCCS) is inviting public feedback on the proposed acquisition of SGX-listed TalkMed Group by Tamarind Health.

CCCS on Jan 13 accepted a joint application from the parties for a decision on whether the proposed transaction would be anti-competitive.

Medical group Tamarind Health had announced on Dec 23, 2024 an offer to purchase shares in TalkMed Group at 45.6 cents per share, valuing the latter at over $606 million.

In Singapore, Tamarind Health is active in medical oncology and other healthcare-related businesses, specifically, surgical oncology, cardiology, and post-cancer services. Outside of Singapore, the company operates post-cancer services and consultation services in Malaysia, medical and radiation oncology services in the Philippines, and oncology services in Hong Kong SAR.

TalkMed provides medical oncology services, treatment of adult and paediatric blood disorders and haematologic malignancies and palliative healthcare services under its main operating entity the Parkway Cancer Centre. 

Shares in TalkMed last changed hands at 45 cents, 1.21% higher year-to-date.

The company first flagged the possibility of an offer on Apr 6, 2024. Since then, the group of doctors who founded TalkMed, with a total stake of 83.06% between them, have given their irrevocable understanding to sell their shares. 

The CCCS is inviting public feedback on the proposed transaction from Jan 21 to Jan 31, 5.00 pm.`